Thalassemia intermedia: Revisited

Blood Cells, Molecules, and Diseases

Volumn 37, Issue 1, 2006, Pages 12-20

  Taher, Ali ^a   Isma'eel, Hussain ^a   Cappellini, Maria D ^b  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Complications; Management; Thalassemia intermedia; Transfusions

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; DEFERASIROX; DEFEROXAMINE; IRON CHELATING AGENT; LOW MOLECULAR WEIGHT HEPARIN; PENTOXIFYLLINE; SILDENAFIL; ZINC;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ARTERY OCCLUSION; ARTICLE; BLOOD TRANSFUSION; BONE MARROW TRANSPLANTATION; CHOLECYSTECTOMY; CONGESTIVE HEART FAILURE; CREATININE BLOOD LEVEL; DEEP VEIN THROMBOSIS; DISEASE COURSE; DRUG ERUPTION; ENDOCRINE FUNCTION; EXTRAMEDULLARY HEMATOPOIESIS; GALLSTONE; GASTROINTESTINAL DISEASE; GENOTYPE PHENOTYPE CORRELATION; HEMOGLOBIN SYNTHESIS; HEPATITIS; HUMAN; INFERTILITY; IRON CHELATION; LEG ULCER; LUNG EMBOLISM; MOLECULAR MECHANICS; PATHOPHYSIOLOGY; PREGNANCY; PRIORITY JOURNAL; PROPHYLAXIS; PULMONARY HYPERTENSION; SPLENECTOMY; SPLENOMEGALY; THALASSEMIA; THALASSEMIA INTERMEDIA; THROMBOPHILIA;

BETA-THALASSEMIA; BLOOD TRANSFUSION; GALLSTONES; HEMATOPOIESIS, EXTRAMEDULLARY; HUMANS; LEG ULCER; THROMBOPHILIA;

EID: 33745941206     PISSN: 10799796     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcmd.2006.04.005     Document Type: Article

References (88)

1. Galanello R., and Cao A. Relationship between genotype and phenotype. Thalassemia intermedia. Ann. N. Y. Acad. Sci. 850 (1998) 325-333
2. Camaschella C., and Cappellini M.D. Thalassemia intermedia. Haematologica 80 (1995) 58-68
3. Weatherall D. The molecular basis for phenotypic variability of the common thalassaemias. Mol. Med. Today 1 (1995) 15-20
4. Camaschella C., Mazza U., Roetto A., et al. Genetic interactions in thalassemia intermedia: analysis of beta-mutations, alpha-genotype, gamma-promoters, and beta-LCR hypersensitive sites 2 and 4 in Italian patients. Am. J. Hematol. 48 (1995) 82-87
5. Camaschella C., Kattamis A.C., Petroni D., et al. Different hematological phenotypes caused by the interaction of triplicated alpha-globin genes and heterozygous beta-thalassemia. Am. J. Hematol. 55 (1997) 83-88
6. Sampietro M., Cazzola M., Cappellini M.D., and Fiorelli G. The triplicated alpha-gene locus and heterozygous beta thalassaemia: a case of thalassaemia intermedia. Br. J. Haematol. 55 (1983) 709-710
7. Wainscoat J.S., Thein S.L., and Weatherall D.J. Thalassaemia intermedia. Blood Rev. 1 (1987) 273-279
8. Kattamis C., Metaxotou-Mavromati A., Ladis V., et al. The clinical phenotype of beta and delta beta thalassemias in Greece. Eur. J. Pediatr. 139 (1982) 135-138
9. Thein S.L. Genetic insights into the clinical diversity of beta thalassaemia. Br. J. Haematol. 124 (2004) 264-274
10. Weatherall D.J. Phenotype-genotype relationships in monogenic disease: lessons from the thalassaemias. Nat. Rev., Genet. 2 (2001) 245-255
11. Weatherall D.J. Thalassemia intermedia: cellular and molecular aspects. J.Hematol. 86 Suppl. 1 (2001) 186-188
12. Ho P.J., Hall G.W., Luo L.Y., et al. Beta-thalassaemia intermedia: is it possible consistently to predict phenotype from genotype?. Br. J. Haematol. 100 (1998) 70-78
13. Rund D., Oron-Karni V., Filon D., et al. Genetic analysis of beta-thalassemia intermedia in Israel: diversity of mechanisms and unpredictability of phenotype. Am. J. Hematol. 54 (1997) 16-22
14. Phadke S.R., and Agarwal S. Phenotype score to grade the severity of thalassemia intermedia. Indian J. Pediatr. 70 (2003) 477-481
15. Olivieri N.F. The beta-thalassemias. N. Engl. J. Med. 341 (1999) 99-109
16. Cappellini M.D., Cerino M., Marelli S., and Fiorelli G. Thalassemia intermedia: clinical aspects and management. Haematologica 86 Suppl. 1 (2001) 194-196
17. Cappellini M.D. The adult thalassemic patient. Hematol. J. (2002) 65-69
18. Borgna-Pignatti C., Rigon F., Merlo L., et al. Thalassemia minor, the Gilbert mutation, and the risk of gallstones. Haematologica 88 (2003) 1106-1109
19. Premawardhena A., Fisher C.A., Fathiu F., et al. Genetic determinants of jaundice and gallstones in haemoglobin E beta thalassaemia. Lancet 357 (2001) 1945-1946
20. Galanello R., Piras S., Barella S., et al. Cholelithiasis and Gilbert's syndrome in homozygous beta-thalassaemia. Br. J. Haematol. 115 (2001) 926-928
21. Chehal A., Aoun E., Koussa S., et al. Hypertransfusion: a successful method of treatment in thalassemia intermedia patients with spinal cord compression secondary to extramedullary hematopoiesis. Spine 28 (2003) E245-E249
22. Castelli R., Graziadei G., Karimi M., and Cappellini M.D. Intrathoracic masses due to extramedullary hematopoiesis. Am. J. Med. Sci. 328 (2004) 299-303
23. Pantongrag-Brown L., and Suwanwela N. Case report: chronic spinal cord compression from extramedullary haematopoiesis in thalassaemia-MRI findings. Clin. Radiol. 46 (1992) 281-283
24. Issaragrisil S., Piankigagum A., and Wasi P. Spinal cord compression in thalassemia. Report of 12 cases and recommendations for treatment. Arch. Intern. Med. 141 (1981) 1033-1036
25. Fucharoen S., Suthipongchai S., Poungvarin N., et al. Intracranial extramedullary hematopoiesis inducing epilepsy in a patient with beta-thalassemia-hemoglobin E. Arch. Intern Med. 145 (1985) 739-742
26. Smith P.R., Manjoney D.L., Teitcher J.B., et al. Massive hemothorax due to intrathoracic extramedullary hematopoiesis in a patient with thalassemia intermedia. Chest 94 (1988) 658-660
27. Saxon B.R., Rees D., and Olivieri N.F. Regression of extramedullary haemopoiesis and augmentation of fetal haemoglobin concentration during hydroxyurea therapy in beta thalassaemia. Br. J. Haematol. 101 (1998) 416-419
28. Cario H., Wegener M., Debatin K.M., and Kohne E. Treatment with hydroxyurea in thalassemia intermedia with paravertebral pseudotumors of extramedullary hematopoiesis. Ann. Hematol. 81 (2002) 478-482
29. Saghafi M., Shirdel A., and Lari S.M. Extramedullary hematopoiesis with spinal cord compression in beta-thalassemia intermedia. Eur. J. Intern. Med. 16 (2005) 596-597
30. Karimi M., Darzi H., and Yavarian M. Hematologic and clinical responses of thalassemia intermedia patients to hydroxyurea during 6 years of therapy in Iran. J. Pediatr. Hematol. Oncol. 27 (2005) 380-385
31. Gupta V.L., and Choubey B.S. RBC survival, zinc deficiency, and efficacy of zinc therapy in sickle cell disease. Birth Defects Orig. Artic. Ser. 23 (1987) 477-483
32. Dettelbach H.R., and Aviado D.M. Clinical pharmacology of pentoxifylline with special reference to its hemorrheologic effect for the treatment of intermittent claudication. J. Clin. Pharmacol. 25 (1985) 8-26
33. al Momen A.K. Recombinant human erythropoietin induced rapid healing of a chronic leg ulcer in a patient with sickle cell disease. Acta Haematol. 86 (1991) 46-48
34. Gimmon Z., Wexler M.R., and Rachmilewitz E.A. Juvenile leg ulceration in beta-thalassemia major and intermedia. Plast. Reconstr. Surg. 69 (1982) 320-325
35. Taher A., Mehio G., Bignamini D., et al. The incidence of thromboembolic events among 8860 patients with thalassemia major and intermedia in the Mediterranean area and Iran. Blood 104 11 (2004) 985a (abst 3623)
36. Eldor A., and Rachmilewitz E.A. The hypercoagulable state in thalassemia. Blood 99 (2002) 36-43
37. Cappellini M.D., Robbiolo L., Bottasso B.M., et al. Venous thromboembolism and hypercoagulability in splenectomized patients with thalassaemia intermedia. Br. J. Haematol. 111 (2000) 467-473
38. Taher A., Abou-Mourad Y., Abchee A., et al. Pulmonary thromboembolism in beta-thalassemia intermedia: are we aware of this complication?. Hemoglobin 26 (2002) 107-112
39. Atichartakarn V., Angchaisuksiri P., Aryurachai K., et al. Relationship between hypercoagulable state and erythrocyte phosphatidylserine exposure in splenectomized haemoglobin E/beta-thalassaemic patients. Br. J. Haematol. 118 (2002) 893-898
40. Eldor A., Lellouche F., Goldfarb A., Rachmilewitz E.A., and Maclouf J. In vivo platelet activation in beta-thalassemia major reflected by increased platelet-thromboxane urinary metabolites. Blood 77 (1991) 1749-1753
41. Aessopos A., Farmakis D., Karagiorga M., et al. Cardiac involvement in thalassemia intermedia: a multicenter study. Blood 97 (2001) 3411-3416
42. Atichartakarn V., Likittanasombat K., Chuncharunee S., et al. Pulmonary arterial hypertension in previously splenectomized patients with beta-thalassemic disorders. Int. J. Hematol. 78 (2003) 139-145
43. Atichartakarn V., Chuncharunee S., Chandanamattha P., et al. Correction of hypercoagulability and amelioration of pulmonary arterial hypertension by chronic blood transfusion in an asplenic hemoglobin E/beta-thalassemia patient. Blood 103 (2004) 2844-2846
44. Aessopos A., Farmakis D., Deftereos S., et al. Thalassemia heart disease: a comparative evaluation of thalassemia major and thalassemia intermedia. Chest 127 (2005) 1523-1530
45. Gharzuddine W.S., Kazma H.K., Nuwayhid I.A., et al. Doppler characterization of left ventricular diastolic function in beta-thalassaemia major. Evidence for an early stage of impaired relaxation. Eur. J. Echocardiog. 3 (2002) 47-51
46. Derchi G., Forni G.L., Formisano F., et al. Efficacy and safety of sildenafil in the treatment of severe pulmonary hypertension in patients with hemoglobinopathies. Haematologica 90 (2005) 452-458
47. De S., Tangerini V.A., Testa M.R., et al. Final height and endocrine function in thalassaemia intermedia. J. Pediatr. Endocrinol. Metab. 11 Suppl. 3 (1998) 965-971
48. Savona-Ventura C., and Bonello F. Beta-thalassemia syndromes and pregnancy. Obstet. Gynecol. Surv. 49 (1994) 129-137
49. Skordis N., Christou S., Koliou M., et al. Fertility in female patients with thalassemia. J. Pediatr. Endocrinol. Metab. 11 Suppl. 3 (1998) 935-943
50. Karagiorga-Lagana M. Fertility in thalassemia: the Greek experience. J.Pediatr. Endocrinol. Metab. 11 Suppl. 3 (1998) 945-951
51. Nassar A., Rechdan J., Usta I., and Taher A. Pregnancy in patients with beta-thalassemia intermedia: outcome of mothers and newborns. SMFM 25th Annual Scientific Meeting (2005) (abst 126700)
52. Spanos T., Karageorga M., Ladis V., et al. Red cell alloantibodies in patients with thalassemia. Vox Sang. 58 (1990) 50-55
53. Hmida S., Mojaat N., Maamar M., et al. Red cell alloantibodies in patients with haemoglobinopathies. Nouv. Rev. Fr. Hematol. 36 (1994) 363-366
54. Pippard M.J., Callender S.T., Warner G.T., and Weatherall D.J. Iron absorption and loading in beta-thalassaemia intermedia. Lancet 2 (1979) 819-821
55. Cossu P., Toccafondi C., Vardeu F., et al. Iron overload and desferrioxamine chelation therapy in beta-thalassemia intermedia. Eur. J. Pediatr. 137 (1981) 267-271
56. Brittenham G.M., Griffith P.M., Nienhuis A.W., et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N. Engl. J. Med. 331 (1994) 567-573
57. Treadwell M.J., and Weissman L. Improving adherence with deferoxamine regimens for patients receiving chronic transfusion therapy. Semin. Hematol. 38 (2001) 77-84
58. Mourad F.H., Hoffbrand A.V., Sheikh-Taha M., et al. Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients. Br. J. Haematol. 121 (2003) 187-189
59. Cappellini M.D. Overcoming the challenge of patient compliance with iron chelation therapy. Semin. Hematol. 42 (2005) S19-S21
60. Borgna-Pignatti C., Cappellini M.D., De Stefano P., et al. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood 107 (2006) 3733-3737
61. Pennell D.J., Berdoukas V., Karagiorga M., et al. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood 107 (2006) 3738-3744
62. Wu K.H., Chang J.S., Tsai C.H., and Peng C.T. Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with beta-thalassemia major. Ann. Hematol. 83 (2004) 471-473
63. Link G., Konijn A.M., Breuer W., Cabantchik Z.I., and Hershko C. Exploring the "iron shuttle" hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture. J. Lab. Clin. Med. 138 (2001) 130-138
64. Ceci A., Baiardi P., Felisi M., et al. The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients. Br. J. Haematol. 118 (2002) 330-336
65. Cohen A.R., Galanello R., Piga A., et al. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood 102 (2003) 1583-1587
66. Richardson D.R. Deferiprone: greater efficacy at depleting myocardial than hepatic iron?. Lancet 360 (2002) 501-502
67. Exjade (Deferasirox) Prescribing Information (2005), Novartis Pharmaceuticals Corporation. http://www.exjade.com http://www.exjade.com
68. Cappellini M.D., Cohen A., Piga A., et al. A Phase III study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 107 (2006) 3455-3462
69. Olivieri N.F., and Brittenham G.M. Iron-chelating therapy and the treatment of thalassemia. Blood 89 (1997) 739-761
70. Fiorelli G., Fargion S., Piperno A., et al. Iron metabolism in thalassemia intermedia. Haematologica 75 Suppl. 5 (1990) 89-95
71. Mancosu M.G., Galanello R., Ambu R., et al. Histological picture of liver disease in thalassemia intermedia. Pathologica 92 (2000) 241-248
72. Jensen P.D. Evaluation of iron overload. Br. J. Haematol. 124 (2004) 697-711
73. Kushner J.P., Porter J.P., and Olivieri N.F. Secondary iron overload. Hematology (Am. Soc. Hematol. Educ. Program) (2001) 47-61
74. Olivieri N.F., Koren G., Matsui D., et al. Reduction of tissue iron stores and normalization of serum ferritin during treatment with the oral iron chelator L1 in thalassemia intermedia. Blood 79 (1992) 2741-2748
75. Piga A., Longo F., Voi V., et al. Late effects of bone marrow transplantation for thalassemia. Ann. N. Y. Acad. Sci. 850 (1998) 294-299
76. Apperley J.F. Bone marrow transplant for the haemoglobinopathies: past, present and future. Bailliere's Clin. Haematol. 6 (1993) 299-325
77. Uckan D., Cetin M., Yigitkanli I., et al. Life-threatening neurological complications after bone marrow transplantation in children. Bone Marrow Transplant. 35 (2005) 71-76
78. Khojasteh N.H., Zakernia M., Ramzi M., and Haghshenas M. Bone marrow transplantation for hematological disorders-Shiraz experience. Indian J. Pediatr. 69 (2002) 31-32
79. Rund D., and Rachmilewitz E. Advances in the pathophysiology and treatment of thalassemia. Crit. Rev. Oncol. Hematol. 20 (1995) 237-254
80. Olivieri N.F. Reactivation of fetal hemoglobin in patients with beta-thalassemia. Semin. Hematol. 33 (1996) 24-42
81. Arruda V.R., Lima C.S., Saad S.T., and Costa F.F. Successful use of hydroxyurea in beta-thalassemia major. N. Engl. J. Med. 336 (1997) 964
82. Bradai M., Abad M.T., Pissard S., et al. Hydroxyurea can eliminate transfusion requirements in children with severe beta-thalassemia. Blood 102 (2003) 1529-1530
83. Dixit A., Chatterjee T.C., Mishra P., et al. Hydroxyurea in thalassemia intermedia-a promising therapy. Ann. Hematol. 84 (2005) 441-446
84. Perrine S.P., Ginder G.D., Faller D.V., et al. A short-term trial of butyrate to stimulate fetal-globin-gene expression in the beta-globin disorders. N. Engl. J. Med. 328 (1993) 81-86
85. Cappellini M.D., Graziadei G., Ciceri L., et al. Oral isobutyramide therapy in patients with thalassemia intermedia: results of a phase II open study. Blood Cells Mol. Dis. 26 (2000) 105-111
86. Sher G.D., Ginder G.D., Little J., et al. Extended therapy with intravenous arginine butyrate in patients with beta-hemoglobinopathies. N. Engl. J. Med. 332 (1995) 1606-1610
87. Collins A.F., Pearson H.A., Giardina P., et al. Oral sodium phenylbutyrate therapy in homozygous beta thalassemia: a clinical trial. Blood 85 (1995) 43-49
88. Olivieri N.F., Rees D.C., Ginder G.D., et al. Treatment of thalassaemia major with phenylbutyrate and hydroxyurea. Lancet 350 (1997) 491-492